Tenderwize
Retour à la recherche

Non-exclusive Drug Discount Agreement for Cinnarizin/Dimenhydrinat

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Apr 30, 2027 · 245 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Cinnarizin/Dimenhydrinat (ATC-Code nach WHO: N07CA52; amtlicher ATC: N07CA22)

40/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

40 / 100

Complexité

30 / 100

Facteurs de risque

No guaranteed quantities; actual demand depends on patient numbers, prescription behavior, and pharmacy stocking. Reven...

AOK PLUS may terminate the Open-House procedure if exclusive agreements are signed, typically 8-12 months after notice...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Apr 2027
  • Supply of pharmaceutical products containing Cinnarizin/Dimenhydrinat (ATC N07CA52/N07CA22) under non-exclusive discount agreements.
  • Participation via Open-House model; no negotiations.
Afficher le résumé complet

Non-exclusive drug discount agreement (Rabattvereinbarung) under §130a Abs.8 SGB V for Cinnarizin/Dimenhydrinat (ATC N07CA52/N07CA22) via an Open-House model. Issued by AOK PLUS for Saxony and Thuringia. No guaranteed volumes or exclusivity. Multiple submission deadlines; first deadline 2025-05-05. Contract runs until 30.04.2027. Open to all pharmaceutical undertakings meeting requirements. No estimated value provided. Award criteria not specified. Selection criteria: self-declaration of no exclusion grounds (GWB) and Russia sanctions compliance.

Risques

No guaranteed quantities; actual demand depends on patient numbers, prescription behavior, and pharmacy stocking. Reven...

AOK PLUS may terminate the Open-House procedure if exclusive agreements are signed, typically 8-12 months after notice...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical undertaking as defined in §4 Abs.18 AMG.

Eligibility

  • Must submit self-declaration of no exclusion grounds (§§123,124 GWB).

Administrative

  • Must submit self-declaration regarding EU Russia sanctions (Art.5k Regulation 833/2014).

Les exigences peuvent être incomplètes.

Acheteur

Localisation

Erfurt, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE256878834

Activité

Health

Lots (1)

LOT-0001

Non-exclusive Drug Discount Agreement for Cinnarizin/Dimenhydrinat

Open-House model for concluding non-exclusive discount agreements for the active substance Cinnarizin/Dimenhydrinat. No guaranteed minimum quantities, no exclusivity. Contract end date 30.04.2027. Place of performance: Dresden, Saxony/Thuringia, Germany.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Dresden, Germany

Durée

May 2025 - Apr 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Apr 30, 2027

Détails de la procédure

Date de publication
24 Mar 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
190844-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30